No, you cannot use enoxaparin instead of warfarin for long-term anticoagulation in rheumatic mitral stenosis with atrial fibrillation.
For patients with atrial fibrillation and rheumatic mitral stenosis, long-term vitamin K antagonist (warfarin) oral anticoagulation is the only recommended therapy 1. This is a Class I, Level C recommendation from the 2020 ACC/AHA Valvular Heart Disease Guidelines, representing the highest strength of recommendation.
Why Warfarin is Mandatory
Rheumatic mitral stenosis with AF represents a uniquely high thromboembolic risk population that has been specifically excluded from all major NOAC trials 1. The guidelines explicitly state that NOACs should not be used in this population, and enoxaparin (a low-molecular-weight heparin) is similarly not appropriate for chronic anticoagulation in this setting.
The FDA labeling for warfarin specifically states: "For patients with AF and mitral stenosis, anticoagulation with oral warfarin is recommended" 2. The target INR should be 2.0-3.0 (target 2.5).
Role of Enoxaparin (Limited and Temporary Only)
Enoxaparin has no role in long-term anticoagulation for rheumatic mitral stenosis with AF. Its only acceptable uses in this population are:
- Bridging therapy during temporary warfarin interruption for procedures 3, 4
- Initial anticoagulation while warfarin is being loaded to therapeutic INR
- Short-term management when warfarin must be held perioperatively
The evidence for enoxaparin is limited to bridging scenarios in mechanical valve patients and AF patients undergoing procedures 4, not as chronic therapy replacement.
What About DOACs/NOACs?
While recent observational data suggests DOACs might be safe in rheumatic MS 5, 6, the highest quality evidence contradicts this. A large 2024 randomized trial (n=4,531) showed that warfarin led to significantly lower rates of cardiovascular events or mortality compared to rivaroxaban in moderate-to-severe MS, without higher bleeding rates 7. This reinforces current guideline recommendations against NOAC use.
Critical Pitfalls to Avoid
- Do not substitute enoxaparin for warfarin thinking it's "easier" - enoxaparin is not validated for chronic use in this population
- Do not use NOACs despite emerging data - the most recent large RCT showed worse outcomes 7
- Do not underdose warfarin - maintain INR 2.0-3.0 consistently
- Do not stop monitoring - INR should be checked at least monthly when stable 8
The Bottom Line
Start warfarin with a target INR of 2.0-3.0 1, 2. Enoxaparin can only be used temporarily during warfarin initiation or for procedural bridging, never as a long-term replacement. The combination of rheumatic mitral stenosis and atrial fibrillation creates such high stroke risk that only warfarin has proven efficacy and safety for chronic anticoagulation.